Regeneron Pharmaceuticals Inc (RGO.SG)

Compare

655.40

-16.20

(-2.41%)

At close: 7:33:34 PM GMT+1

$Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma$

Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

TARRYTOWN, N.Y., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of linvoseltamab to treat adults with relapsed and refractory (R/R) multiple myeloma (MM). The recommendation is specific to those who have received at least three prior therapies, including a proteasome inhib

GlobeNewswire 3 days ago

REGN
Regeneron makes second bid for blood cancer therapy approval

The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July 2025.

Pharmaceutical Technology 4 days ago

REGN

GLDAF
$Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma$

Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma

FDA decision expected by July 30, 2025TARRYTOWN, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in relapsed/refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. The target action date for the FDA decision is July 30, 2025. Acceptance of the BLA resubmission fo

GlobeNewswire 5 days ago

REGN
Regeneron Pharmaceuticals, Inc. (REGN): Among the Stocks That Will Go to The Moon According to Analysts

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. The Stock Market Under Trump Admin While stocks initially fell based on worries regarding Trump tariffs on […]

Insider Monkey 6 days ago

REGN
Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial

As presented at ARO, 10 of 11 children with at least one post-treatment assessment showed notable improvements in hearing Speech and development progress followed dramatic improvements in hearing in first child treated in the trial TARRYTOWN, N.Y., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have profound genetic hearing loss due to varia

GlobeNewswire 7 days ago

REGN
Regeneron Pharmaceuticals (REGN): Among the Best Growth Stocks to Invest In According to Analysts

We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best growth stocks to invest in according to analysts. Companies experiencing above-average earnings growth, which is often fueled by innovations […]

Insider Monkey 7 days ago

REGN
The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis

Merck, Sanofi, Regeneron and Ionis are included in this Analyst Blog.

Zacks 7 days ago

SNY

REGN
2 Healthcare Stocks with Big Upside and 1 to Skip

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry has tumbled by 1.7% over the last six months. This drawdown is a stark contrast from the S&P 500’s 9% gain.

StockStory 10 days ago

REGN

ZTS

MRK
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea

Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 treatment for eye disorders, which could compete with Regeneron Pharmaceuticals’ Eylea.

Investopedia 13 days ago

TEVA

REGN
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.

Zacks 13 days ago

SNY

REGN

ALNY
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues.

Pharmaceutical Technology 13 days ago

SNY

REGN

GLDAF
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrating significant improvements in sustained disease remission with Dupixent compared to placebo BP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation characterized by intense itch and blisters, reddening of the skin and painful lesions TARRYTOWN, N.Y. and PARIS,

GlobeNewswire 13 days ago

REGN
Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y

ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher product sales.

Zacks 17 days ago

ALNY

REGN
Regeneron Pharmaceuticals' (NASDAQ:REGN) earnings growth rate lags the 11% CAGR delivered to shareholders

While Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) shareholders are probably generally happy, the stock hasn't had...

Simply Wall St. 18 days ago

REGN
Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 45th Annual Health Care Conference at 11:50 a.m. ET on Tuesday, March 4, 2025Leerink Partners 2025 Global Healthcare Conference at 8:00 a.m. ET on Tuesday, March 11, 2025 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of

GlobeNewswire 19 days ago

REGN
$Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma$

Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma

Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least fo

GlobeNewswire 20 days ago

REGN
Regeneron’s macular oedema therapy shows promise in Phase III trial

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Clinical Trials Arena 21 days ago

REGN
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. While it can be hard to separate the wheat from the chaff, let's consider three companies, all in the biotech industry, that were market losers last year but could recover given enough time: CRISPR Therapeutics (NASDAQ: CRSP), Amgen (NASDAQ: AMGN), and Regeneron (NASDAQ: REGN). CRISPR Therapeutics is the gene-editing specialist that created Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed with Vertex Pharmaceuticals.

Motley Fool 21 days ago

AMGN

REGN

CRSP
Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock

The fact that multiple Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders offloaded a considerable amount of...

Simply Wall St. 22 days ago

REGN
Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings tomorrow before the bell. Here’s what to expect.

StockStory 22 days ago

INCY

REGN

ABBV

Performance Overview

Return	RGO.SG	S&P 500
YTD	-3.15%	-0.54%
1-Year	-26.59%	+13.87%
3-Year	+18.63%	+34.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Regeneron Pharmaceuticals Inc (RGO.SG)

Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

Regeneron makes second bid for blood cancer therapy approval

Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma

Regeneron Pharmaceuticals, Inc. (REGN): Among the Stocks That Will Go to The Moon According to Analysts

Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial

Regeneron Pharmaceuticals (REGN): Among the Best Growth Stocks to Invest In According to Analysts

The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis

2 Healthcare Stocks with Big Upside and 1 to Skip

FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea

SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag

FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y

Regeneron Pharmaceuticals' (NASDAQ:REGN) earnings growth rate lags the 11% CAGR delivered to shareholders

Regeneron Announces Investor Conference Presentations

Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron’s macular oedema therapy shows promise in Phase III trial

Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move

Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock

Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow

Performance Overview